Introduction: In neuroendocrine tumor (NET), complete surgery could better the prognosis of this disease: radioguided surgery (RGS) with beta-radioisotopes, as 90Y, is a novel approach focused on developing a new probe which, detecting electrons and operating with low background, provides a clearer delineation of the margins of lesions with low radiation exposition for surgeons.
Aim(s): To validate this RGS procedure, tests on ex vivo specimens of tumors expressing somatostatin receptors as small-intestine neuroendocrine (SI-NET) were performed.
Materials and methods: We studied these tumors due to the high uptake of 90Y-DOTATOC, a beta- emitting radiotracer. Patients were enrolled according to the tumor Standard Uptake Value (SUV) and the expected Tumor to Non-tumor Ratio (TNR) estimated from 68Ga-DOTATOC PET/CT images. Five SI-NET patients were submitted to PET/CT and entero-CT scan, 2 weeks prior to surgery. Twenty-four hours before surgery, patients received 5 mCi of 90Y-DOTATOC.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Chiara Maria Grana
Grana C M
, Bertani E
, Collamati F
, Faccini R
, Pisa E
, Morganti S
, Ferrari M E
, Papi S
, Funicelli L
, Colandrea M
, Fumagalli R U
, Fazio N
To read results and conclusion, please login ...
Further abstracts you may be interested in